Ebola Outbreak 2026: Cases Surge in DRC as WHO Approves First Diagnostic Test

Ebola Outbreak 2026: Cases Surge in DRC as WHO Approves First Diagnostic Test

The 2026 Ebola outbreak caused by the Bundibugyo virus (BVD) continues to escalate in the Democratic Republic of the Congo, with the World Health Organization now reporting more than 1,460 confirmed cases and 452 deaths. As the outbreak enters its most critical phase, WHO has taken the unprecedented step of adding the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing — a move that could reshape containment efforts across the affected region.

This is the largest recorded outbreak of Ebola disease caused by Bundibugyo virus, and it shows no signs of slowing. Since mid-June 2026, new cases have surged dramatically, driven in part by expanded surveillance and testing capacity, but also by ongoing transmission in highly populated and conflict-affected areas of eastern DRC.

The Outbreak by the Numbers

As of 1 July 2026, the outbreak has affected 36 health zones across three provinces in the DRC — Ituri, North Kivu, and South Kivu. Ituri Province remains the epicentre, accounting for 91.3% of all confirmed cases and 84% of reported deaths. The hardest-hit areas include:

• Bunia — 416 confirmed cases
• Rwampara — 308 confirmed cases
• Mongbwalu — 270 confirmed cases
• Nyankunde — 95 confirmed cases
• Nizi — 65 confirmed cases

The outbreak has now spread to three additional health zones in Ituri Province, and cases have been detected in Haut Uele and Tshopo provinces, indicating geographical expansion beyond the original hotspots. More than 10,800 contacts are currently under follow-up across Ituri and North Kivu.

Uganda and International Spread

Uganda has reported 20 confirmed cases and two deaths since the outbreak began, with the last confirmed case identified on 21 June 2026. Of these, 15 cases were imported from the DRC, while five involved secondary transmission among contacts and healthcare workers. Uganda’s response has been effective — 821 of 831 listed contacts have completed their 21-day follow-up period, and there is no evidence of community transmission.

However, the international dimension of this outbreak became sharply real on 24 June 2026, when French authorities notified WHO of a laboratory-confirmed case of Bundibugyo virus disease in a medical doctor returning from the DRC. The patient had been deployed for five weeks in Ituri Province caring for BVD patients. Upon arrival at Charles de Gaulle Airport, he self-reported symptoms and was immediately isolated. This case underscores the very real risk of international spread through air travel.

Healthcare Workers on the Front Line

Healthcare workers continue to bear a disproportionate burden in this outbreak. To date, 102 confirmed cases including 25 deaths have been reported among health and care workers in the DRC. Infection rates among healthcare personnel highlight critical gaps in infection prevention and control measures, particularly in facilities operating in conflict zones with limited resources.

The outbreak is unfolding in a complex humanitarian environment characterised by highly mobile and often displaced populations, many lacking access to basic services such as food, clean water, shelter, and healthcare. Overcrowded internally displaced persons camps pose an elevated risk of transmission, and increasing security incidents affecting health facilities have further constrained response operations.

WHO Approves First Diagnostic Test

On 2 July 2026, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing. The test detects the virus by identifying its genetic material in blood samples, enabling rapid and accurate confirmation of infection.

Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, emphasised the importance of this milestone: “Public health emergencies require not only speed, but also confidence that the health products being used meet standards for quality, safety and performance. During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission.”

WHO declared a Public Health Emergency of International Concern (PHEIC) on 17 May 2026, and called for manufacturers to submit Expressions of Interest for diagnostic tests shortly afterward. With support from WHO and Africa CDC, laboratory testing capacity has expanded from a handful of sites capable of 200–400 tests per day to a network of 10 laboratories across affected provinces, now capable of more than 2,000 tests daily.

No Approved Vaccine or Treatment

Unlike the Zaire strain of Ebola, for which effective vaccines and treatments exist, there are currently no approved vaccines or specific treatments for Bundibugyo virus disease. Early supportive care — including fluid and electrolyte replacement, oxygen therapy, and treatment of complications — remains the cornerstone of clinical management and significantly improves survival outcomes.

The crude case fatality ratio currently stands at 30.9%, though this figure is influenced by enhanced surveillance detecting milder cases that may previously have been missed. At least 229 patients have recovered to date.

Research into therapeutics and vaccines for BVD is ongoing, with WHO and partners including PATH, FIND, and CHAI working to establish a joint validation platform to evaluate diagnostic products, near-point-of-care tests, and antigen rapid diagnostic tests for use in outbreak settings.

CDC Issues Travel Guidance

The United States Centers for Disease Control and Prevention has issued interim guidance for the public health assessment and management of travelers arriving from affected countries. The DRC, Uganda, and neighbouring South Sudan are included in the guidance. Federal public health staff are conducting initial assessments for air passengers arriving from or transiting through affected countries at designated US airports. Health departments are advised to establish communication with arriving travelers within 24 hours of notification.

Symptoms of Bundibugyo virus disease include fever, fatigue, muscle pain, headache, and sore throat, followed by vomiting, diarrhoea, rash, and in severe cases, internal and external bleeding. The incubation period ranges from 2 to 21 days.

Frequently Asked Questions

What is Bundibugyo virus disease?

Bundibugyo virus disease (BVD) is a severe, often fatal illness caused by the Bundibugyo virus, one of three Ebola virus species known to cause large outbreaks in humans. It is a viral hemorrhagic fever transmitted through contact with infected bodily fluids.

How is Bundibugyo virus transmitted?

The virus can spread from animals (likely bats or non-human primates) to humans, and then from person to person through direct contact with blood, secretions, organs, or other bodily fluids of infected people, as well as surfaces and materials contaminated with these fluids. Burial practices that involve contact with the deceased pose a high transmission risk.

Is there a vaccine for Bundibugyo virus?

No. Unlike the Zaire ebolavirus strain (for which the Ervebo vaccine is approved), there is currently no licensed vaccine for Bundibugyo virus. Research is ongoing.

What treatments are available?

There are no specific antiviral treatments approved for BVD. Early supportive care — including intravenous fluids, oxygen, blood pressure management, and treatment of secondary infections — significantly improves survival rates.

Should I be concerned about travel?

Travelers to affected regions in eastern DRC and Uganda should follow guidance from WHO and CDC. Avoid contact with symptomatic individuals, healthcare facilities in outbreak zones, and animals such as bats and non-human primates. Practice rigorous hand hygiene and monitor for symptoms for 21 days after leaving affected areas.

What is WHO’s Emergency Use Listing?

WHO’s Emergency Use Listing (EUL) is a mechanism that assesses the quality, safety, and performance of essential health products during public health emergencies. It enables accelerated access to reliable diagnostic tools and supports procurement agencies in making informed decisions.

Conclusion

The 2026 Bundibugyo virus outbreak represents a major global health emergency that demands sustained international attention. With cases continuing to rise, the approval of the first diagnostic test is a vital step forward, but significant gaps remain — particularly the absence of vaccines and treatments for this Ebola strain. Strengthening surveillance, protecting healthcare workers, and ensuring rapid diagnostic capacity across the region will be critical to bringing this outbreak under control.